AI assistant
GENEDRIVE PLC — Director's Dealing 2017
Apr 5, 2017
7668_rns_2017-04-05_5087961f-6228-4bc1-aa87-e188ced2469a.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6825B
Genedrive PLC
05 April 2017
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them - Replacement
The following amendments have been made to the 'Director/PDMR Shareholding' announcement released today at 11:17am under RNS No 6708B.
50,000 options were granted to each of Allan Brown and Gino Miele and not 117,647.
All other details remain unchanged.
The full amended text is shown below,
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to certain of its directors and senior management to acquire a total of 632,884 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
1. David Budd
2. Allan Brown
3. Gino Miele
2.
Reason for the notification
a.
Position/status
1. Chief Executive Officer
2. Chief Operating Officer
3. R&D Director
a.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
genedrive plc
b.
LEI
N/A
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type
of instrument
Identification code
Options over ordinary shares of 1.5 pence each
b.
Nature of the transaction
Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 28 November 2007.
c.
Price(s) and volume(s)
| Price(s) | Option price(s) | Volume(s) |
| David Budd | 42.5p | 397,590 |
| Allan Brown | 42.5p | 50,000 |
| Gino Miele | 42.5p | 50,000 |
d.
Aggregated information
· Aggregated volume
· Price
N/A
e.
Date of the transaction
2016-04-04; UTC time
f.
Place of the transaction
Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options
For further details please contact:
| genedrive plc | +44 (0)161 989 0245 |
| David Budd: CEO | |
| Matthew Fowler: CFO | |
| Peel Hunt LLP | +44 (0)207 418 8900 |
| James Steel | |
| Oliver Jackson | |
| Consilium Strategic Communications | +44 (0)203 709 5700 |
| Chris Gardner | |
| Matthew Neal | |
| Laura Thornton | |
| [email protected] |
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSSLFFIFWSEDL